{
    "clinical_study": {
        "@rank": "43543", 
        "acronym": "rhLAMAN-09", 
        "arm_group": {
            "arm_group_label": "Lamazym", 
            "arm_group_type": "Experimental", 
            "description": "1 mg Lamazym/kg body weight"
        }, 
        "brief_summary": {
            "textblock": "The overall objective of this trial is to provide aftercare treatment with Lamazym and to\n      evaluate the safety of repeated Lamazym i.v. treatment of subjects with alpha-Mannosidosis\n      whom previously participated in Lamazym-trial."
        }, 
        "brief_title": "Lamazym Aftercare Study", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Alpha-Mannosidosis", 
        "condition_browse": {
            "mesh_term": [
                "Alpha-Mannosidosis", 
                "Mannosidase Deficiency Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This protocol only concern subjects from Poland, where compassionate use program was not\n      accepted. Efficacy will be evaluated once yearly to follow the subject's progress in\n      clinical parameters."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  the subject must have participated in previous Lamazym-trials: phase 2b:\n             2011-004355-40 or phase 3: 2012-000979-17\n\n          -  Subject or subjects legally authorized guardian(s) must provide signed, informed\n             consent prior to performing any trial-related activities\n\n          -  The subject and his/her guardian(s) must have the ability to comply with the protocol\n\n        Exclusion Criteria:\n\n          -  Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal\n             disease or other medical conditions that, in the opinion of the Investigator, would\n             preclude participation in the trial\n\n          -  Any other medical condition or serious intercurrent illness, or extenuating\n             circumstances that, in the opinion of the Investigator, would preclude participation\n             in the trial\n\n          -  Pregnancy. Pregnant woman is excluded. Before start fot he treatment the\n             investigators will for women of childbearing potential perform a pregnancy test and\n             decide whether or not there is a need for contraception\n\n          -  Psychosis; any psychotic disease, also in remission, is an exclusion criteria\n\n          -  Planned major surgery that, in the opinion of the Investigator, would preclude\n             participation in the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01908725", 
            "org_study_id": "rhLAMAN-09", 
            "secondary_id": "2013-000321-31"
        }, 
        "intervention": {
            "arm_group_label": "Lamazym", 
            "description": "ERT, i.v. infusions weekly", 
            "intervention_name": "Lamazym", 
            "intervention_type": "Drug", 
            "other_name": [
                "rhLAMAN", 
                "recombinant human alpha-mannosidase"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 23, 2013", 
        "link": {
            "description": "12th international symposium on MPS and related diseases", 
            "url": "http://www.google.dk/url?sa=t&rct=j&q=line%20borgwardt&source=web&cd=1&cad=rja&sqi=2&ved=0CCsQtwIwAA&url=http%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DZGgqK7oJQFQ&ei=4TG4UejWD8SSO7TqgbAI&usg=AFQjCNG4azVFYvyGp-yNBeoP4tG6YQQ1Tw&bvm=bv.47810305,d.ZWU"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "zip": "DK-2100"
                }, 
                "name": "Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials", 
        "overall_official": {
            "affiliation": "Copenhagen University Hospital, Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre", 
            "last_name": "Allan M Lund, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AE documented at all visits", 
                "measure": "Change from baseline in Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "3 year"
            }, 
            {
                "description": "AB measured every 12th week", 
                "measure": "Change from baseline in Lamazym antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "3 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01908725"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "progress from baseline in number of steps climbed in 3 minutes", 
                "safety_issue": "No", 
                "time_frame": "1 year, 2 year and 3 year"
            }, 
            {
                "measure": "Progress from baseline in equivalent age", 
                "safety_issue": "No", 
                "time_frame": "1 year, 2 year and 3 year"
            }, 
            {
                "measure": "Progress from baseline in Forced Vital Capacity", 
                "safety_issue": "No", 
                "time_frame": "1 year, 2 year and 3 year"
            }, 
            {
                "measure": "Progress from baseline in distance walked in 6 minutes", 
                "safety_issue": "No", 
                "time_frame": "1 year, 2 year and 3 year"
            }
        ], 
        "source": "Zymenex A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zymenex A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}